Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 15/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.37 |
| ▸ | CLK1 | P49759 | 1/20 | 0.37 |
| ▸ | CLK2 | P49760 | 1/20 | 0.37 |
| ▸ | CLK3 | P49761 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.37 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.37 |
| ▸ | PNCK | Q6P2M8 | 1/20 | 0.37 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.37 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.37 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.37 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4259756 | 0.79 | TAAR1 (0.40) | TAAR1KDM4EMAPT | |
| SCHEMBL11318303 | 0.76 | TDP1 (0.49) | TAAR1LMNAKDM4EMAPT | |
| SCHEMBL22576537 | 0.76 | TAAR1 (0.38) | TAAR1 | |
| SCHEMBL2578411 | 0.76 | DYRK1A (0.45) | TAAR1DYRK1AJAK3 | |
| SCHEMBL6462366 | 0.76 | TAAR1 (0.41) | TAAR1DYRK1A | |
| SCHEMBL4263326 | 0.74 | POLB (0.42) | TAAR1HSD17B10MAPT | |
| SCHEMBL1586782 | 0.73 | DYRK1A (0.42) | DYRK1ALMNACYP1A2THRBBLM | |
| SCHEMBL4268865 | 0.73 | NCF1 (0.45) | DYRK1ALMNACYP1A2THRBBLM | |
| SCHEMBL29740313 | 0.73 | NCF1 (0.45) | DYRK1ALMNACYP1A2THRBBLM | |
| SCHEMBL25687569 | 0.73 | CYP2D6 (0.42) | TAAR1LMNACYP1A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104817534-A | Novel hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors | ALTANA PHARMA AG | 2015-08-05 | — | — | CN | claimed |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | INITIAL THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| WO-2024226875-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS | INITIAL THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| CN-105745214-B | Tricyclic piperidine compounds | 埃科特莱茵药品有限公司 | 2019-02-19 | — | — | CN | disclosed |
| CN-104817534-A | Novel hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors | ALTANA PHARMA AG | 2015-08-05 | — | — | CN | disclosed |
| CN-104803974-A | Novel hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors | TAKEDA GMBH | 2015-07-29 | — | — | CN | disclosed |
| CN-104803973-A | Novel hydroxy-6-heteroarylphenanthridines and their use as pde4 inhibitors | TAKEDA GMBH | 2015-07-29 | — | — | CN | disclosed |
| CN-104761545-A | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | TAKEDA GMBH | 2015-07-08 | — | — | CN | disclosed |
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMECUTICAL CO., LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1730122-A2 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005095357-A2 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2005-10-13 | — | — | WO | disclosed |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
| WO-2004087669-A1 | NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO. LTD. (JP) | 2004-10-14 | — | — | WO | disclosed |
| EP-1464335-A2 | Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist | Taisho Pharmaceutical Co. Ltd. (JP) | 2004-10-06 | — | — | EP | disclosed |
| WO-2004074278-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-09-02 | — | — | WO | disclosed |
| EP-0001981-B1 | 9-(OMEGA-HETEROARYLAMINO-ALKYLAMINO)-ERYTHROMYCINS, THEIR SALTS, PROCESSES FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | Dr. Karl Thomae GmbH (DE) | 1981-04-01 | — | — | EP | disclosed |
| US-4256738-A | BACTERICIDES, PYRIMIDINYL, QUINAZOLINYL | BOEHRINGER INGELHEIM GMBH (DE) | 1981-03-17 | — | — | US | disclosed |
| EP-0001981-A1 | 9-(Omega-heteroarylamino-alkylamino)-erythromycins, their salts, processes for their preparation and medicaments containing them | Dr. Karl Thomae GmbH (DE) | 1979-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | TAAR1 37/4885DYRK1A 1129/4885LMNA 3391/4885 |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | MYCBP, MYC, MYCBP2 | TAAR1 4773/4885DYRK1A 4646/4885LMNA 1281/4885 |
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | GPR119, HCRTR2, MCHR1 | TAAR1 35/4885DYRK1A 2347/4885LMNA 2888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.